CRISPR-based genome editing has transformed biological research. Since the advent of the technology in 2012, Addgene has ...
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive ...
Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global ...
The CEO of Caszyme, a biotech company in Vilnius, Lithuania, presented details of Cas12l, a novel compact Cas nuclease with a ...
The new CRISPR platform, called ΨDNA, reprograms Cas12 nucleases to recognize and act on RNA using a DNA-based guide scaffold ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
MIT scientists have found a way to make gene editing far safer and more accurate — a breakthrough that could reshape how we treat hundreds of genetic diseases. By fine-tuning the tiny molecular “tools ...
On April 14, 2026, the United States Food and Drug Administration (“FDA”) issued a draft guidance for sponsors seeking approval of human ...
One‑and‑done gene edit cut LDL up to 62%; Cleveland labs flag a nitric‑oxide Alzheimer clue. Experts caution on supplements.
14d
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc. Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results